Prostate Cancer Imaging with 18F-Fluciclovine

PET Clin. 2022 Oct;17(4):607-620. doi: 10.1016/j.cpet.2022.07.005.

Abstract

18F-Fluciclovine PET is approved for the evaluation of patients with suspected prostate cancer recurrence. 18F-Fluciclovine PET is highly specific for the localization of extraprostatic disease even with negative conventional images and low prostate-specific antigen and has been reported to influence patients' management and improve outcome. With the recent Food and Drug Administration approval of prostate-specific membrane antigen (PSMA) PET, 18F-Fluciclovine is likely to be used as an adjunct modality in patients with suspected occult local recurrence and/or negative PSMA findings.

Keywords: FACBC; Fluciclovine; PET/CT; PET/MR; Prostate cancer.

Publication types

  • Review

MeSH terms

  • Carboxylic Acids
  • Cyclobutanes*
  • Humans
  • Male
  • Positron Emission Tomography Computed Tomography / methods
  • Prostate
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / diagnostic imaging

Substances

  • Carboxylic Acids
  • Cyclobutanes
  • fluciclovine F-18
  • Prostate-Specific Antigen